Abbott Laboratories $ABT Stock Sold by Bokf Na

Key Points

• Bokf Na reduced its Abbott Laboratories stake by 12.5% in the third quarter, selling 12,500 shares and retaining 87,770 shares valued at approximately $8.7 million. Institutional investors collectively own 75.18% of the company.
• Analysts maintain a generally positive view, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $118.32, despite several recent target reductions and an Argus downgrade to Hold.
• Abbott reported quarterly earnings of $1.42 per share and revenue of $13.01 billion, while highlighting potential growth initiatives including its Cephea mitral-valve trial and next-generation Oncodetect cancer test.

Bokf Na lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 87,770 shares of the healthcare product maker's stock after selling 12,500 shares during the quarter. Bokf Na's holdings in Abbott Laboratories were worth $8,674,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Foresight Capital Management Advisors Inc. bought a new position in shares of Abbott Laboratories in the 3rd quarter worth $31,000. Manning & Napier Advisors LLC bought a new stake in Abbott Laboratories in the second quarter valued at about $31,000. Balance Wealth Partners LLC acquired a new position in Abbott Laboratories in the third quarter valued at about $34,000. Summit Securities Group LLC lifted its stake in Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker's stock valued at $37,000 after buying an additional 118 shares during the period. Finally, Addison Advisors LLC bought a new position in Abbott Laboratories during the second quarter worth about $40,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, September 18th. Citigroup cut their price target on shares of Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating on the stock in a research report on Thursday, October 22nd. TD Cowen reduced their price objective on shares of Abbott Laboratories from $135.00 to $118.00 and set a "buy" rating on the stock in a research note on Thursday, October 22nd. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Thursday, October 22nd. Finally, Barclays started coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They issued an "overweight" rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $118.32.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott initiated the pivotal CROWN-MV trial for its investigational Cephea™ Mitral Valve System. The minimally invasive device targets symptomatic mitral valve disease patients who are not eligible for surgery or existing transcatheter repair, creating a potential future growth opportunity in structural heart care. However, the device remains investigational and commercialization is still dependent on trial results and regulatory approval. Abbott initiates pivotal trial for Cephea device
• Positive Sentiment: The company launched a next-generation Oncodetect test designed to detect residual cancer disease. The release reinforces Abbott’s diagnostics pipeline and could support longer-term growth if the test gains clinical adoption. Abbott launches next-generation Oncodetect test
• Positive Sentiment: Abbott reportedly received approximately $23.9 million in net ETF buying, indicating some institutional demand for the shares, although ETF flows are not a measure of operating performance. Abbott sees net ETF buying
• Neutral Sentiment: Abbott’s planned separation of its roughly $8.5 billion Nutrition business could allow management to focus more closely on medical devices, diagnostics and pharmaceuticals, but it would also remove a sizable source of revenue diversification. The transaction remains subject to regulatory and internal approvals. Potential Abbott Nutrition spin-off
• Neutral Sentiment: Industry reports project growth in South and Central American point-of-care diagnostics and European medical foods, markets in which Abbott participates. These reports provide favorable demand context but do not represent new company-specific contracts or guidance.
• Negative Sentiment: Argus Research downgraded Abbott from Buy to Hold, potentially limiting near-term upside and signaling a less favorable risk-reward assessment. Argus downgrades Abbott to Hold

Abbott Laboratories Price Performance

Shares of ABT opened at $104.37 on Friday. The stock has a 50 day simple moving average of $104.52 and a 200 day simple moving average of $102.15. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $180.60 billion, a PE ratio of 19.08, a P/E/G ratio of 1.80 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. The firm had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business's quarterly revenue was up 14.5% on a year-over-year basis. During the same period last year, the company posted $1.30 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories's dividend payout ratio (DPR) is presently 94.03%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.